Houston, TXNCT04216524Now EnrollingIRB Ready

Blastic Plasmacytoid Dendritic Cell Neoplasm Clinical Trial in Houston, TX

Access cutting-edge blastic plasmacytoid dendritic cell neoplasm treatment through this clinical trial at a research site in Houston. Study-provided care at no cost to qualified participants.

Sponsored by M.D. Anderson Cancer Center

Quick Self-Assessment

See if you qualify for this Houston location

Preparing your pre-screening questions…

Expert Care in Houston

Access blastic plasmacytoid dendritic cell neoplasm specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related blastic plasmacytoid dendritic cell neoplasm treatment provided free

Apply for This Houston Location

Check if you qualify for this blastic plasmacytoid dendritic cell neoplasm clinical trial in Houston, TX

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Houston

    Convenient for TX residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Houston site if eligible
  4. 4Begin participation

About This Blastic Plasmacytoid Dendritic Cell Neoplasm Study in Houston

This phase II trial studies how well venetoclax, SL-401, and chemotherapy works in treating patients with blastic plasmacytoid dendritic cell neoplasm. Venetoclax may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. SL-401 is a recombinant protein consisting of IL-3 linked to a toxic agent called DT. IL-3 attaches to IL-3 receptors on tumor cells in a targeted way and delivers DT to kill them. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving venetoclax and SL-401 with chemotherapy may be an effective treatment for patients with blastic plasmacytoid dendritic cell neoplasm.

Sponsor: M.D. Anderson Cancer Center

Who Can Participate

Inclusion Criteria

Treatment naïve or relapsed refractory patients with histologically confirmed diagnosis of blastic plasmacytoid dendritic cell neoplasm (BPDCN) per 2016 WHO criteria
Front line participants may have received emergent chemotherapy prior to study enrollment:
One prior cycle of SL-401, or other BPDCN-directed therapy, will be allowed prior to entering the study.
Prior or concomitant doses of ARA-C (cytarabine) or Hydroxyurea are allowed on before or during the study for proliferative disease due to BPDCN.
Relapsed/refractory participants may have received at least one prior cycle of therapy.
Age ≥ 18 years
ECOG performance status 0, 1, or 2 (see APPENDIX B)
Adequate organ function as defined by:
Albumin ≥ 3.2 g/dL (in the absence of receipt of intravenous albumin in the previous 72 hours)
Serum creatinine \< 1.5x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \< 2.5x ULN
Total bilirubin \< 1.5x ULN (if total bilirubin is \> 1.5x but \< 3x ULN, and thought to be elevated due to Gilbert's disease or the patient's BPDCN, the subject may be eligible but must discuss with the PI)
Ability to understand and the willingness to sign a written informed consent document.
Able to adhere to study visit schedule and other protocol requirements including follow-up for survival assessment
Women of child-bearing potential and men enrolled on this protocol must agree to use adequate contraception for the duration of study participation and for 2 months after completion VEN administration. Acceptable birth control methods allowed to be used while on study include:
Birth control pills or injections
Intrauterine devices (IUDs)
Double-barrier methods for example condom in combination with spermicide. Males should not donate sperm while on study and for at least 8 weeks after the last dose of SL-401.
Left ventricular ejection fraction ≥ institutional lower limit of normal by MUGA scan or echocardiogram within 30 days of first protocol treatment.

Exclusion Criteria

Participants is pregnant or breastfeeding
Known active hepatitis B or C infection, or known seropositivity for human immunodeficiency virus (HIV)
Major surgery or radiation therapy within 14 days prior to the first study dose
Symptomatic or untreated leptomeningeal disease or spinal cord compression
Participants with active heart disease (New York Heart Association (NYHA) class 3-4 as assessed by history and physical examination, unstable angina/stroke/myocardial infarction within the last 6 months)
Malabsorption syndrome or other conditions that preclude enteral route of administration
Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that in the opinion of the investigator may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and/or would make the participants inappropriate for enrollment into this study

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Houston?

Yes, this clinical trial (NCT04216524) has an active research site in Houston, TX that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Blastic Plasmacytoid Dendritic Cell Neoplasm Treatment Options in Houston, TX

If you're searching for blastic plasmacytoid dendritic cell neoplasm treatment options in Houston, TX, this clinical trial (NCT04216524) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Houston research site is actively enrolling participants for this clinical trial. You'll receive care from experienced blastic plasmacytoid dendritic cell neoplasm specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all blastic plasmacytoid dendritic cell neoplasm clinical trials near you to find additional studies recruiting in your area.

More Ankylosing Spondylitis Trials in Houston, TX

See all ankylosing spondylitis clinical trials recruiting in Houston — not just this study.

Browse Ankylosing Spondylitis Trials in Houston →

Browse More Trials by Condition

Ankylosing Spondylitis TrialsInterstitial Cystitis TrialsSpinal Muscular Atrophy TrialsOsteogenesis Imperfecta TrialsAll Conditions →

Ready to Join in Houston?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Houston, TX